MGMT and glioblastoma: For the first time, we report the metabolically driven epigenetic effects of the synergistic combination of SN-38 and checkpoint kinase 1 inhibitor (CHK1), rabusertib, in both +MGMT and −MGMT GBM cell lines, suggesting a promising candidate for combinatorial therapy in GBM.